Altered microRNA expression in mycosis fungoides

Maj, Joanna; Jankowska‐Konsur, Alina; Sadakierska‐Chudy, Anna; Noga, Leszek; Reich, Adam

doi:10.1111/j.1365-2133.2011.10669.x

Cited by 33 publications

(36 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Patients were of a variety of carcinomas, including breast cancer, pancreatic ductal adenocarcinomas, esophageal cancer, hepatocellular carcinoma, leukemia, colorectal cancer, lung cancer and lymphoma. Of all the 28 studies, 16 studies (n = 2536) with HR data could be included for metaanalysis [7,[13][14][15][16][17][18][33][34][35][36][37][38][39][40][41]. Among them, seven studies (n = 1678) recruited lung cancer patients.…”

Section: Resultsmentioning

confidence: 99%

Prognostic Role of microRNA-155 in Various Carcinomas: Results from a Meta-Analysis

Zhang

et al. 2013

Disease Markers

View full text Add to dashboard Cite

Abstract. BACKGROUND:Recent studies have shown that microRNAs (miRNA) have prognostic values in cancers. This meta-analysis seeks to summarize the global predicting role of miR-155 for survival in patients with a variety of carcinomas. METHODS: Eligible studies were identified through multiple search strategies. Data were extracted from studies investigating the relationship between miR-155 expression and survival in cancer patients. Combined hazard ratios (HRs) of miR-155 for outcome were analyzed. RESULTS: A total of 16 studies dealing with various carcinomas were included for this meta-analysis. For overall survival, higher miR-155 expression could significantly predict worse outcome with the pooled HR of 2.057 (95% CI: 1.392-3.039). For relapse or progress-free survival, elevated miR-155 was also a significant predictor, with a combined HR of 1.918 (95% CI: 1.311-2.806,). In addition, subgroup analysis showed that higher expression of miR-155 had the trends to predict worse outcome in lung cancer. However, the HRs did not reach the statistical significance. CONCLUSION: Our findings suggest that miR-155 detection has a prognostic value in cancer patients. Regularly measuring miR-155 expression may be useful in clinical practice.

show abstract

Section: Resultsmentioning

confidence: 99%

Prognostic Role of microRNA-155 in Various Carcinomas: Results from a Meta-Analysis

Zhang

et al. 2013

Disease Markers

View full text Add to dashboard Cite

show abstract

“…They may have oncogenic or tumor suppressing properties depending on their target genes (6,7). Several studies have demonstrated specific miRNA expression profiles in different types of CTCL suggesting a role in the pathogenesis of these disorders (8)(9)(10)(11)(12). For instance, recently, van Kester et al (8) have elaborated on the miRNA expression profile of tumor-stage mycosis fungoides (MF), a CTCL with a 10-year DSS of 42%.…”

Section: Introductionmentioning

confidence: 99%

Primary cutaneous anaplastic large cell lymphoma shows a distinct miRNA expression profile and reveals differences from tumor‐stage mycosis fungoides

Benner

Ballabio

Kester

et al. 2012

Experimental Dermatology

View full text Add to dashboard Cite

The miRNA expression profiles of skin biopsies from 14 primary cutaneous anaplastic large cell lymphoma (C-ALCL) patients were analysed with miRNA microarrays using the same control group of 12 benign inflammatory dermatoses (BID) as previously used to study the miRNA expression profile of tumorstage mycosis fungoides (MF). We identified 13 differentially expressed miRNAs between C-ALCL and BID. The up-regulation of miR-155, miR-27b, miR-30c and miR-29b in C-ALCL was validated by miRNA-Q-PCR on independent study groups. Additionally, the miRNA expression profiles of C-ALCL were compared with those of tumor-stage MF. Although miRNA microarray analysis did not identify statistically significant differentially expressed miRNAs, miRNA-Q-PCR demonstrated statistically significantly differential expression of miR-155, miR-27b, miR-93, miR-29b and miR-92a between tumor-stage MF and C-ALCL. This study, the first describing the miRNA expression profile of C-ALCL, reveals differences with tumor-stage MF, suggesting a different contribution to the pathogenesis of these lymphomas.

show abstract

“…Ralfkiaer et al (14) found that miR-155 was one of the most significantly upregulated miRs in several types of cutaneous T-cell lymphoma (CTCL) including MF compared with inflammatory skin diseases. The comparison between early stage and advanced stage has been described recently by Maj et al (15). No significant difference was found in miR-155 expression between early and advanced stage.…”

Section: Introductionmentioning

confidence: 99%

“…Accumulating evidence shows that miR-155 is an oncogenic miR that was found to be overexpressed in various solid tumors and in B-cell lymphoid malignancies (5)(6)(7)(8)(9)(10)(11). Studies of the role of miR-155 in T-cell lymphomas in general and MF in particular are strikingly sparse (12)(13)(14)(15). Van Kester et al (13) found miR-155 to be upregulated in tumor-stage MF compared with benign inflammatory dermatoses (13).…”

Section: Introductionmentioning

confidence: 99%

miR‐155 is involved in tumor progression of mycosis fungoides

Moyal

Barzilai

Gorovitz

et al. 2013

Experimental Dermatology

View full text Add to dashboard Cite

Biopsy specimens from 23 early stage and 19 tumorstage mycosis fungoides (MF) patients were evaluated for miR-155 expression by real-time qualitative PCR and compared with 15 biopsy specimens from patients with T-cell-rich inflammatory skin diseases. Significant upregulation of miR-155 was found in MF tumors compared with both early-stage MF lesions and controls. There was no difference in miR-155 expression between early-stage and inflammatory dermatoses. Using laser capture microdissection, it was found that miR-155 was significantly higher in the lymphoma cells in tumor stage compared with the intraepidermal lymphocytes in early stage. In contrast, there was no difference in miR-155 expression between the intraepidermal lymphocytes and the dermal lymphocytes in early-stage MF.These findings suggest that although miR-155 expression cannot serve to discriminate early-stage MF from inflammatory dermatoses; however, it is involved in the switch from the indolent early stage into the aggressive tumor stage of the disease.Abbreviations: CTCL, cutaneous T cell lymphoma; MF, mycosis fungoides; SS, sezary syndrome; FFPE, formalin fixed paraffin embedded; LCM, laser capture microdissection; DLE, discoid lupus erythematosus.

show abstract

Altered microRNA expression in mycosis fungoides

Abstract: Altered expression of studied microRNAs and the differences between early and advanced MF may suggest that microRNAs play a significant role in MF pathogenesis. It seems that microRNAs could serve as potential therapeutic targets in the future.

Cited by 33 publications

References 45 publications

Prognostic Role of microRNA-155 in Various Carcinomas: Results from a Meta-Analysis

Prognostic Role of microRNA-155 in Various Carcinomas: Results from a Meta-Analysis

Primary cutaneous anaplastic large cell lymphoma shows a distinct miRNA expression profile and reveals differences from tumor‐stage mycosis fungoides

miR‐155 is involved in tumor progression of mycosis fungoides

Contact Info

Product

Resources

About